EXEL250516C37000
- 0.80
- -0.70-46.67%
Exelixis Newsroom
Earnings Preview: Exelixis to Report Financial Results Post-market on May 13
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Top Gap Ups and Downs on Wednesday: SAN, SBUX, MDLZ and More
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
Press Release: Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Is the Market Bullish or Bearish on Exelixis?
William Blair Maintains Exelixis(EXEL.US) With Buy Rating
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Express News | Exelixis Inc : Leerink Partners Raises Target Price to $35 From $33
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)
New Analyst Forecast: $EXEL Given 'Underperform' Rating
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $42
Exelixis (EXEL) Gets a Buy From RBC Capital
Top Gap Ups and Downs on Friday: BBVA, MFG, NWG and More
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now?
Exelixis Launches Special Equity Award Program
Guggenheim Remains a Buy on Exelixis (EXEL)